{"id":520347,"date":"2021-07-29T16:13:11","date_gmt":"2021-07-29T20:13:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/"},"modified":"2021-07-29T16:13:11","modified_gmt":"2021-07-29T20:13:11","slug":"arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/","title":{"rendered":"Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights <\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><i>Company to Host Conference Call on Thursday, August 5, 2021, at 1:30 pm PT\/4:30 pm ET<\/i><\/li>\n<\/ul>\n<p>HAYWARD, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nArcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the company will report its financial results for the second quarter ended June 30, 2021 after the market closes on Thursday, August 5, 2021.\n<\/p>\n<p>\nManagement will host a conference call on August 5, 2021 to discuss second quarter 2021 financial results and recent corporate highlights. The call will begin at 1:30 pm PT\/ 4:30 pm ET. Investors interested in listening to the conference call may do so by dialing (844) 200-6205 in the U.S. or +44 208 0682 558 internationally, using Conference ID: 152804. In addition, the live webcast and any accompanying slides will be available on the \u201cInvestors\u201d section of the Arcus website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.arcusbio.com&amp;esheet=52468580&amp;newsitemid=20210729005982&amp;lan=en-US&amp;anchor=www.arcusbio.com&amp;index=1&amp;md5=90fef7bfddabaffc946d2ff6dcab859d\">www.arcusbio.com<\/a>. Following the live webcast, a replay will be available on the Company&#8217;s website for at least two weeks following the live event.\n<\/p>\n<p><b>About Arcus Biosciences<\/b><\/p>\n<p>\nArcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has five molecules in clinical development: <b>Etrumadenant (AB928)<\/b>, the first dual A<sub>2a<\/sub>\/A<sub>2b <\/sub>adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, and pancreatic cancers. <b>AB680<\/b>, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1\/1b development in combination with zimberelimab and gemcitabine\/nab-paclitaxel for first-line treatment of metastatic pancreatic cancer. <b>Domvanalimab (AB154) <\/b>is an Fc-silent anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy. In addition to ARC-7, domvanalimab is being investigated in a registrational, Phase 3 study, ARC-10, a \u201ctwo in one trial\u201d to support the potential approvals of both zimberelimab alone and domvanalimab plus zimberelimab compared to chemotherapy in first-line locally advanced or metastatic, PD-L1&gt;50% NSCLC. An additional registrational Phase 3 study is being planned in collaboration with AstraZeneca in earlier disease with curative intent. <b>AB308<\/b>, an anti-TIGIT antibody that is Fc-enabled, is in clinical development, with a potential focus on hematological malignancies. <b>Zimberelimab (AB122)<\/b>, Arcus\u2019s anti-PD-1 monoclonal antibody, is being evaluated in various combinations across the portfolio. For more information about Arcus Biosciences, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.arcusbio.com&amp;esheet=52468580&amp;newsitemid=20210729005982&amp;lan=en-US&amp;anchor=www.arcusbio.com&amp;index=2&amp;md5=3990d54c4e2b86062e6ee5e2a767d76c\">www.arcusbio.com<\/a>.\n<\/p>\n<p>\nSource: Arcus Biosciences\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210729005982r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210729005982\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210729005982\/en\/<\/a><\/span><\/p>\n<p><b>Investor Inquiries:<br \/>\n<\/b><br \/>Katherine Bock<br \/>\n<br \/>VP Investor Relations &amp; Corporate Strategy<br \/>\n<br \/>(510) 694-6231<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:kbock@arcusbio.com\">kbock@arcusbio.com<\/a><\/p>\n<p><b>Media Inquiries:<br \/>\n<\/b><br \/>Holli Kolkey<br \/>\n<br \/>VP of Corporate Communications<br \/>\n<br \/>(650) 922-1269<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:hkolkey@arcusbio.com\">hkolkey@arcusbio.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210729005982\/en\/895138\/3\/ARCUS_Logo_RGB_1920x1080.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights Company to Host Conference Call on Thursday, August 5, 2021, at 1:30 pm PT\/4:30 pm ET HAYWARD, Calif.&#8211;(BUSINESS WIRE)&#8211; Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the company will report its financial results for the second quarter ended June 30, 2021 after the market closes on Thursday, August 5, 2021. Management will host a conference call on August 5, 2021 to discuss second quarter 2021 financial results and recent corporate highlights. The call will begin at 1:30 pm PT\/ 4:30 pm ET. Investors interested in listening to the conference call may do so by dialing (844) 200-6205 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-520347","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights Company to Host Conference Call on Thursday, August 5, 2021, at 1:30 pm PT\/4:30 pm ET HAYWARD, Calif.&#8211;(BUSINESS WIRE)&#8211; Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the company will report its financial results for the second quarter ended June 30, 2021 after the market closes on Thursday, August 5, 2021. Management will host a conference call on August 5, 2021 to discuss second quarter 2021 financial results and recent corporate highlights. The call will begin at 1:30 pm PT\/ 4:30 pm ET. Investors interested in listening to the conference call may do so by dialing (844) 200-6205 &hellip; Continue reading &quot;Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-29T20:13:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210729005982r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights\",\"datePublished\":\"2021-07-29T20:13:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\\\/\"},\"wordCount\":461,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210729005982r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\\\/\",\"name\":\"Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210729005982r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-07-29T20:13:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210729005982r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210729005982r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/","og_locale":"en_US","og_type":"article","og_title":"Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights - Market Newsdesk","og_description":"Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights Company to Host Conference Call on Thursday, August 5, 2021, at 1:30 pm PT\/4:30 pm ET HAYWARD, Calif.&#8211;(BUSINESS WIRE)&#8211; Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the company will report its financial results for the second quarter ended June 30, 2021 after the market closes on Thursday, August 5, 2021. Management will host a conference call on August 5, 2021 to discuss second quarter 2021 financial results and recent corporate highlights. The call will begin at 1:30 pm PT\/ 4:30 pm ET. Investors interested in listening to the conference call may do so by dialing (844) 200-6205 &hellip; Continue reading \"Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-29T20:13:11+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210729005982r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights","datePublished":"2021-07-29T20:13:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/"},"wordCount":461,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210729005982r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/","name":"Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210729005982r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-07-29T20:13:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210729005982r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210729005982r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-to-report-second-quarter-2021-financial-results-recent-corporate-highlights\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arcus Biosciences to Report Second Quarter 2021 Financial Results &amp; Recent Corporate Highlights"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/520347","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=520347"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/520347\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=520347"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=520347"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=520347"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}